AiCure

Nycomed

UCB to sell generics business to private equity firms Advent, Avista Capital for $1.525 billion

Monday, November 10, 2014 12:26 PM

Advent International and Avista Capital Partners, two private equity firms with a strong healthcare focus, have agreed to acquire UCB’s U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals (KU). UCB is a multinational biopharmaceutical manufacturing company headquartered in Brussels, Belgium.

More... »


Blaze Bioscience raises $9.8M in Series A financing

Monday, February 25, 2013 10:28 AM

Blaze Bioscience, a Seattle-based biotechnology company focused on cancer, has completed a Series A financing totaling $8.5 million, bringing the total funds raised since inception to $9.8 million.

More... »


Takeda to cut 2,800 jobs as it absorbs Nycomed

Wednesday, January 18, 2012 12:21 PM

Osaka, Japan-based Takeda Pharmaceutical plans to consolidate its R&D site operations and cut its workforce by 2,800 to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth through innovation and culture.

More... »

Regeneron names LaRosa senior VP

Tuesday, September 6, 2011 12:44 PM

Regeneron Pharmaceuticals has named Joseph J. LaRosa senior vice president, general counsel and secretary. LaRosa will be responsible for overseeing all legal affairs, including general corporate legal matters, intellectual property and corporate compliance, and will report to Leonard S. Schleifer, M.D., Ph.D., president and chief executive officer.

More... »

Takeda acquires Nycomed for $13.7 billion

Tuesday, August 2, 2011 12:50 PM

Japanese drug maker Takeda Pharmaceutical secured EU approval for its $13.68 billion acquisition of privately owned Nycomed to reinforce its presence in emerging markets, according to Reuters.

More... »

Takeda acquires Nycomed

Thursday, May 19, 2011 10:45 AM

Japan-based Takeda Pharmaceutical has agreed to buy Switzerland-based Nycomed for $13.6 billion, making it a wholly-owned subsidiary of Takeda.

More... »

Takeda denies takeover of Nycomed

Friday, May 13, 2011 11:35 AM

Japan-based Takeda Pharmaceutical has denied rumors of a $12.3 billion takeover of Switzerland-based Nycomed, according to Pharma Times.

More... »

Nycomed and Almirall partner to market COPD drug

Thursday, May 5, 2011 11:54 AM

Nycomed and Almirall will become marketing partners for the chronic obstructive pulmonary disease (COPD) treatment Daxas. The two firms have entered into a co-branding agreement covering Spain for Daxas (roflumilast), Nycomed's once-daily COPD tablet, according to Pharma Times.

More... »

Nycomed/Forest drug gains FDA approval

Tuesday, March 8, 2011 10:45 AM

The FDA has approved Nycomed and partner Forest Laboratories’ chronic obstructive pulmonary disease drug roflumilast, according to PharmaTimes.

More... »

Ecron Acunova Founder Steps Down

Friday, April 24, 2009 08:29 AM

Ecron Acunova, a CRO based out of Germany, India and the United States, appointed Antal Hajos managing director and CEO Europe, replacing ECRON founder and CEO Klaus Wiedey, who will serve as an advisor to the company. In his new role, Hajos will oversee all business, strategic and operational aspects of the European operations. Prior to joining Ecron Acunova last year, Hajos was director of global clinical operations with Altana Pharma and later CEO of Altana/Nycomed’s research and development center and Indian affiliate in Mumbai, India.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs